Source: Company press release, 8 Jan 2019 , 8 Jan 2019 ,
Website: http://www.biospace.com Biond Biologics Ltd, a
privately-held Israeli biotechnology
company, developing novel immunotherapies for cancer and autoimmune
diseases, announced on 8 Jan 2018 the closing of a $17 M Series B financing.
Biond intends to use the proceeds to move its lead drug candidate, BION-202,
into clinical trials and to advance the preclinical development of BION-206
and its proprietary antibody cell-internalization technology. The financing
and due diligence were led by Israel Biotech Fund and Harel Insurance and
Finance Group, with participation of Celgene Corporation, the
Japanese-Israeli fund, SBI JI Innovation Fund and existing investors.
Original Source: Biond Biologics Ltd, 2019. From website:
http://www.biospace.com. Released to ICIS 12 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey, firstname.lastname@example.org, +44 (0) 1223 463167]